Gatifloxacin

DB01044ApprovedInvestigationalWithdrawnSmall moleculeAnti-Bacterial AgentsQuinolone AntimicrobialQuinolones

Gatifloxacin is a fourth generation fluoroquinolone used to treat a wide variety of infections in the body. Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family.

Chemical structure of Gatifloxacin
Mechanism
Curator reviewed
Primary indication
For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenesCurator reviewed · 3 structured indications
Formula / weight
C19H22FN3O4 · 375.3941 g/mol (avg)
First approval
Canada, 2001 · United States, 2010
Brand names
  • Zymar
  • Zymaxid

Resolves to

Structure
InChIKeyXUBOMFCQGDBHNK-UHFFFAOYSA-NSMILESCOC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1

What you can answer from here — as of September 30, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
974Drug interactionsStructured to mechanism, not free text
Sign in
30Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
51Marketed productsAcross 7 countries and 27 labellers
Sign in
2ATC codesIncluding every combination product, plus 27 drug categories
Sign in
38+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Gatifloxacin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account